Lexaria Biosciences Corp. (NASDAQ: LEXX) stock rises by 18.49% during current market trading. DehydraTECH, a novel drug delivery system developed by Lexaria Biosciences, changes the way active medicinal ingredients reach the bloodstream by encouraging healthier oral absorption approaches and increasing the efficacy of fat-soluble active molecules, resulting in lower total dosing.
What is happening?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LEXX is delighted to report that the first sets of data from its 2021 advanced research and development (R&D) sample programs have shown positive results. Three new “DehydraTECH 2.0” formulation variants were used in the HYPER-A21-1 study to improve cannabidiol delivery accuracy and pharmacokinetics optimization. As opposed to Lexaria’s initial DehydraTECH 1.0 and 2.0 concentration-matched formulations, as well as a medium-chain triglyceride oil-based control formulation indicative of current market standards, the three recent DehydraTECH 2.0 formulations performed better.
Both of the latest DehydraTECH 2.0 formulations provided relatively high rates of CBD penetration into brain tissues, surpassing the levels reached with the MCT oil-based control formulation. The three new DehydraTECH 2.0 formulations provided 907% to 1,737% more CBD into brain tissue than the MCT oil-based control formulation, equivalent to Lexaria’s initial DehydraTECH 2.0 formulation, which delivered up to 1,937% more CBD into brain tissue than the MCT oil-based control formulation.
Additionally,
Lexaria is currently evaluating DehydraTECH 2.0 formulations in study HYPER-A21-2, with findings due in late May or early June 2021. Following that, Lexaria plans to conduct further research to assess the effects of selected formulations on real-time blood pressure in animals as a result of these trials. When more information about the forthcoming blood pressure tests in animals becomes available, Lexaria will provide the update. Lexaria is now using innovative DehydraTECH 2.0 formulations in current human trials, which will be monetized for industrial use when necessary.
